Translational Oncology Program brings novel Phase I oncology trials to community-based cancer centers, providing patients convenient access to advanced treatments
US Oncology Research, one of the largest community-based oncology research programs in the United States specializing in oncology clinical trials, announced it has recruited its 2,000th patient to participate in a Phase I clinical trial through its Translational Oncology Program (TOP).
As part of its announcement, US Oncology Research also recognized Lawrence Garbo, MD, Chair, NYOH Research Committee and Phase I trials, for his outstanding work in connecting eligible NYOH patients with Phase I trials. NYOH has been part of the TOP program since 2006 and today, NYOH offers the largest, most comprehensive clinical research program in the region.
Phase I trials present special challenges to both patients and treatment centers and are rarely found in a community setting. The TOP Program, chaired by oncologist and research scientist Daniel Von Hoff, M.D., F.A.C.P, chief scientific officer of US Oncology Research, provides guidance, resources and support so physicians in community-based cancer centers can successfully offer these complex research studies to their patients. Providing access to these advanced clinical trials close to home allows patients to be near family and friends in a familiar setting, supporting optimal outcomes.
“We have reached a great milestone in our Phase I Translational Oncology Program by recruiting our 2,000th patient,” noted Lisa Holland, VP, US Oncology Research. “It is very challenging for practices to manage these complex trials as well as to connect or reach patients when they are looking for access to more options beyond standard therapies, so this is a major accomplishment. I am very proud of the success of the program and proud to support the hundreds of affiliated physicians who lead the program and who work tirelessly for their patients.”
Phase I clinical trials are designed to investigate whether a new drug or treatment, which has proven to be safe for use in animals, may also be safe for people. Participants are often the first to receive a new investigational therapy or a new combination of therapies. Additionally, these advanced trials can only be conducted at qualified locations that have the experience, facilities, and equipment required to conduct such studies. Because of these complexities, Phase I trials are difficult to operate in a community setting and are usually only available at large university hospitals, making the enrollment of 2,000 patients in the TOP program a significant achievement in the cancer community.
To date, the TOP program has opened more than 130 Phase I trials across the country. It has contributed to the approval of several drugs through Phase I participation including treatments such as azacitidine, ibrutinib, and zydelig.
While finding and enrolling appropriate patients into these complex trials can be quite challenging, several TOP physicians have enrolled a significant number of patients. Donald Richards, M.D., physician researcher with Texas Oncology-Tyler and TOP participant since 2005, leads the list of highest enrolling investigators with 266 patients placed into TOP trials as of March 2015. Other high-accruing physicians include:
- Fadi Braiteh, M.D., 258 patients, Comprehensive Cancer Centers of Nevada, TOP participant since 2008
- Carlos Becerra, M.D., 229 patients, Texas Oncology-Baylor Charles A. Sammons Cancer Center, TOP participant since 2006
- Jeff Edenfield, M.D., 188 patients, Greenville Health System, TOP participant since 2005
- Paul Conkling, M.D., 173 patients, Virginia Oncology Associates, TOP participant since 2005
- Lawrence Garbo, M.D.,130 patients, New York Oncology Hematology, TOP participant since 2006
US Oncology Research has been helping investigators conduct new agent Phase I trials in community-based oncology since 2005 when the Translational Oncology Program was founded. As participants in TOP, physicians and their community-based practices assume a leadership role in the testing of new cancer therapies that provide novel therapeutic treatment and support to patients. The TOP program also provides physicians and nurses experience with the agents early on in the drug development process.
“The Translational Oncology Program physicians and staff are true trailblazers, making an impact against cancer by being on the front line of drug development,” said Dr. Von Hoff. “Enrolling more than 2,000 patients into these TOP Phase I trials is a remarkable achievement that speaks highly of this dedicated team, but the most important thing is that these patients received targeted cancer therapy as early as possible, possibly giving them the best opportunity to attack their disease.”
About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and nearly 165 locations managing about 300 active trials at any given time. Physicians in the research network have enrolled more than 62,000 patients in nearly 1,500 trials since inception in 1992 and have played a role in nearly 60 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information visit www.usoncology.com/oncologists.